Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act
收藏NBER2003-06-01 更新2025-01-04 收录
下载链接：
https://www.nber.org/papers/w9750
下载链接
链接失效反馈官方服务：
资源简介：
With substantial fixed costs of drug development, more common conditions can support more products. If additional pharmaceutical products are beneficial, they will attract greater consumption and promote better health, e.g. greater longevity. We ask how market size measured by condition prevalence
药物研发存在高额固定成本，因此更常见的病症能够支撑更多产品。若额外的药品具有益处，它们将拉动更高的消费量，并促进健康状况改善（例如延长寿命）。我们探讨如何通过疾病患病率来衡量市场规模
提供机构：
美国国家经济研究局
创建时间：
2003-06-01
